A phase i trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 5, 2013, Pages 1273-1285

  Chow, Laura Q M ^a,e   Jonker, Derek I ^a   Dy, Grace K ^b   Nicholas, Garth ^a   Fortin, Catherine ^a   Patricia, Daniel ^c   Adjei, Alex A ^b   Belani, Chandra P ^d   Gupta, Ashok ^c   Park, Jong Soon ^c   Zhang, Steven ^c   Sbar, Eric I ^c   Laurie, Scott A ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

BMS 690514; EGFR; Intercalated therapy; Paclitaxel carboplatin; Phase I; Solid malignancies; Tyrosine kinase inhibitor; VEGFR

Indexed keywords

BMS 690514; CARBOPLATIN; PACLITAXEL; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ACNE; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BLURRED VISION; BRAIN HEMORRHAGE; CHOLELITHIASIS; COHORT ANALYSIS; CONSTIPATION; CONTINUOUS INFUSION; CONVULSION; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGUS PAIN; ESOPHAGUS STENOSIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEPATIC ENCEPHALOPATHY; HOT FLUSH; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OROPHARYNX PAIN; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PRURITUS; RHINORRHEA; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URETER OBSTRUCTION; URINARY TRACT INFECTION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PACLITAXEL; PIPERIDINES; PYRROLES; TREATMENT OUTCOME; TRIAZINES;

EID: 84877924019     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2126-9     Document Type: Article

References (46)

1. Schwartz GN, Pendyala L, Kindler H, Meropol N, Perez R, Raghavan D et al (1998) The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer 34:1543-1548
2. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK (2005) Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer (Amsterdam, Netherlands) 50:355-374
3. Ozols RF (2002) Update on the management of ovarian cancer. Cancer J (Sudbury, Mass) 8(Suppl 1):S22-S30
4. Marathe P, Tang Y, Sleczka B, Rodrigues D, Gavai A, Wong T et al (2010) Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci 99:3579-3593
5. Seymour L (2003) Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics. Curr Opin Investig Drugs 4:658-666
6. Chen P, Wang L, Liu B, Zhang HZ, Liu HC, Zou Z (2011) EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 67:235-243
7. Tsai CM, Chen JT, Stewart DJ, Chiu CH, Lai CL, Hsiao SY et al (2011) Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed? J Thorac Oncol 6:559-568
8. Gatzmeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F et al (2007) Phase III trial of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552
9. Giaccone G, Herbst RS, Manegold C, Kaukel E, Roubec J, De Rosa F et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT1. J Clin Oncol 22:777-784
10. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT2. J Clin Oncol 22:785-794
11. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
12. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
13. Margolin K (2002) Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep 4:20-28
14. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V et al (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21:1804-1809
15. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
17. Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M et al (2011) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004-2010
18. Lee CB, Socinski MA (2007) Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Rev Recent Clin Trials 2:117-120
19. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D et al (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 28:49-55
20. Blumenschein GR, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT et al (2011) A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22:2057-2067
21. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M et al (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842
22. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN et al (2009) Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol 4:862-868
23. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ et al (2001) Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol 6:2112-2119
24. Wong TW, Lee FY, Emanuel S, Fairchild C, Fargnoli J, Fink B et al (2011) Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families. Clin Cancer Res 17:4031-4041
25. Gupta A (2010) ErbB/VEGF Receptor Inhibitor: BMS-690514 Investigator Brochure. Bristol-Myers Squibb Research and Development. Princeton, NJ
26. Chow LQ, Salvati M, Chow P et al (2010) Using FDG-PET in xenograft models to identify dosing regimen in a Phase 1 trial of intercalated BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors (poster presentation 168). Multidisciplinary symposium in thoracic oncology (ASCO/ASTRO/IASLC), Chicago, IL
27. Bahleda R, Felip E, Herbst RS, Hanna NH, Laurie SA, Shepherd FA et al (2008) Phase I multicenter trial of BMS-690514: safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol 26 (suppl; abstr 2564)
28. Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595
29. Loriot Y, Mordant P, Dorvault N, De la motte Rouge T, Bourhis J, Soria JC et al (2010) BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. Br J Cancer 103:347-353
30. Mok TSK, Lee JS, Zhang L, Yu C, Thongprasert S, Ladrera GEI et al (2012) Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, fastact-2 study of intercalated erlotinib with first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 23(Suppl 9):PPIX400-PPIX446
31. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 16:4853-4863
32. Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC et al (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung cancer 69:272-278
33. Langer CJ (2011) Roles of EGFR and KRAS mutations in the treatment of patients with Non-small-cell lung cancer. Pharm Ther 36:263-279
34. Allen-Auerbach M, Weber WA (2009) Measuring response with FDG-PET: methodological aspects. Oncologist 14:369-377
35. Weber WA, Figlin R (2007) Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med 48(Suppl 1):36S-44S
36. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J et al (2009) Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27:439-445
37. Revheim ME, Roe K, Bruland OS, Bach-Gansmo T, Skretting A, Seierstad T (2011) Monitoring the Effect of Targeted Therapies in a Gastrointestinal Stromal Tumor Xenograft Using a Clinical PET/CT. Mol Imaging Biol 13:1234-1240
38. Funck-Brentano C, Jaillon P (1993) Rate-corrected QT interval: techniques and limitations. Am J Cardiol 72(6):17B-22B
39. Christopher LJ, Hong H, Vakkalagadda B, Clemens PL, Su H, Roongta V et al (2010) Metabolism and disposition of [14C]BMS-690514 ((3R,4R)-4-amino-1-((4- ((3-methoxyphenyl)amino)pyrrolo[2,1-f][1, 2, 4]triazin-5-yl)methyl)-3- piperidinol), an ErbB/VEGFR inhibitor, after oral administration to humans. Drug Metab Dispos 38:2049-2059
40. Hong HZ, Su H, Ma L, Yao M, Iyer RA, Humphreys WG et al (2011) In vitro characterization of the metabolic pathways and P450 inhibition and induction potential of BMS-690514, an ErbB/VEGFR inhibitor. Drug Metab Dispos 39:1658-1667
41. Tonkin K, Tritchler D, Tannock I (1985) Criteria of tumor response used in clinical trials of chemotherapy. J Clin Oncol 3:870-875
42. Glusker P, Recht L, Lane B (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982 (discussion-2)
43. Kaneda H, Okamoto I, Satoh T, Nakagawa K (2011) Reversible posterior leukoencephalopathy syndrome and trastuzumab. Invest New Drugs [Epub ahead of print]
44. Martin G, Bellido L, Cruz JJ (2007) Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25:3559
45. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T et al (2007) A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 67:6253-6262
46. Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N et al (2009) Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the Erb/VEGFR inhibitor BMS-690514 [ASCO abstract 8098]. J Clin Oncol 27((15S)):11-12